Table 2.
Univariate analysis results
| Variable | n (%) | PNA,* n (%) | PA,† n (%) | OR (95% CI) | p Value‡ |
| Sex: Male Female |
262 (78.7) 71 (21.3) |
91 (82.0) 20 (18.0) |
172 (77.4) 50 (22.5) |
1.33 (0.75 to 2.37) | 0.333 |
| Age in years, mean (SD) | 49.0 (9) | 48.0 (8.8) | 48.8 (8.8) | 0.99 (0.96 to 1.02) | 0.414 |
| Undetectable plasma viral load (HIV RNA<20 copies/mL) |
259 (77.8) | 88 (79.3) | 171 (77.0) | 0.88 (0.5 to 1.53) | 0.641 |
| SNA to HAART§ | 49 (14.7) | 21 (18.9) | 28 (12.6) | 0.62 (0.87 to 3.0) | 0.132 |
| Number of comorbidities, mean (SD) |
2.3 (1.3) | 2.6 (1.5) | 2.1 (1.2) | 1.34 (1.12 to 1.61) | <0.001 |
| Number of co-medication: mean (SD) |
3.4 (2.7) | 4.2 (3.4) | 3.1 (2.3) | 1.16 (1.07 to 1.26) | <0.001 |
| Antacid therapy | 125 (37.5) | 43 (38.7) | 82 (36.9) | 1.08 (0.67 to 1.73) | 0.749 |
| Psychotropic drugs | 179 (53.8) | 69 (62.2) | 110 (49.5) | 1.67 (1.05 to 2.66) | 0.030 |
| Lipid-lowering drugs | 103 (30.9) | 29 (26.1) | 74 (33.3) | 0.71 (0.43 to 1.17) | 0.181 |
| Cardiovascular therapy | 80 (24.0) | 29 (26.1) | 51 (23.0) | 1.12 (0.65 to 1.89) | 1.186 |
| Antidiabetic drugs | 30 (9) | 9 (8.1) | 21 (9.5) | 0.77 (0.34 to 1.75) | 0.540 |
| Viral liver diseases | 132 (39.6) | 52 (46.8) | 80 (36) | 1.53 (0.97 to 2.44) | 0.070 |
| Dyslipidaemias | 97 (29.1) | 30 (27.0) | 67 (30.2) | 0.86 (0.52 to 1.42) | 0.551 |
| Central nervous system diseases | 85 (25.5) | 28 (25.2) | 57 (25.7) | 0.98 (0.58 to 1.89) | 0.929 |
| Cardiovascular or hypertension diseases | 77 (23.1) | 27 (24.5) | 50 (22.5) | 1.11 (0.65 to 1.89) | 0.713 |
*Patients whose primary adherence failed at least to one concomitant medication.
†Patients with primary adhesion to all concomitant medications.
‡It represents the level of significance between variable and PNA to concomitant treatments.
§Patients whose adhesion percentage to HAART did not exceed 90.0%.
HAART, highly active antiretroviral treatment; PA, primary adherence; PNA, primary non-adherence; SNA, secondary non-adherence.